Straits Times Index
3,294.43 +3.73 (+0.11%) Nikkei
38,243.59 +14.48 (+0.04%) Hang Seng
19,047.81 +84.13 (+0.44%) FTSE 100
8,433.76 +261.61 (+3.20%) Bitcoin USD
60,790.02 -94.77 (-0.16%) CMC Crypto 200
1,257.98 -54.65 (-4.16%)
Equillium Inc (0FY.MU)
| Previous close | 1.5740 |
| Open | 1.5940 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.5940 - 1.5940 |
| 52-week range | 0.4695 - 2.6350 |
| Volume | |
| Avg. volume | 116 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 07 Aug 2024 - 12 Aug 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
ZacksEquillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
Equillium (EQ) delivered earnings and revenue surprises of 52.94% and 16.82%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Business WireEquillium Reports First Quarter 2024 Financial Results and Provides Recent Clinical Highlights
LA JOLLA, Calif., May 09, 2024--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced financial results for the first quarter 2024 and highlights in clinical development.
Business WireEquillium Announces Poster Presentation at the Annual Meeting of The American Association of Immunologists
LA JOLLA, Calif., May 07, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that a poster was presented at IMMUNOLOGY2024, the annual meeting of The American Association of Immunologists. The meetings are taking place at McCormick Place Convention Center in Chicago, Illinois, May 3 – 7.
